(Q43576127)

24 November 2017

title

Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience (English)

1 reference

24 November 2017

1 reference

J P Nobes

1

1 reference

24 November 2017

I G Wells

2

1 reference

24 November 2017

S J Khaksar

3

1 reference

24 November 2017

J F Money-Kyrle

4

1 reference

24 November 2017

R W Laing

5

1 reference

24 November 2017

S E M Langley

6

1 reference

24 November 2017

publication date

22 April 2008

1 reference

Prostate Cancer and Prostatic Diseases

24 November 2017

published in

1 reference

24 November 2017

volume

12

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

61-66

1 reference

Interstitial implantation techniques in prostate cancer

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Prostate brachytherapy has come of age: a review of the technique and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

European collaborative group on prostate brachytherapy: preliminary report in 1175 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Interstitial low dose rate brachytherapy for prostate cancer--a focus on intermediate- and high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Cancer incidence after localized therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Comparison of biochemical failure definitions for permanent prostate brachytherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

The PSA nadir that indicates potential cure after radiotherapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

PSA kinetics and PSA bounce following permanent seed prostate brachytherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

Early voiding dysfunction associated with prostate brachytherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

(125)Iodine prostate brachytherapy: outcome from the first 100 consecutive patients and selection strategies incorporating urodynamics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.17

31 March 2020

Identifiers

DOI

10.1038/PCAN.2008.17

1 reference

Dimensions Publication ID

24 November 2017

1031382070

0 references

1 reference